2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC
  5. Traditional Cytotoxic Agents Isoform

Traditional Cytotoxic Agents

 

Traditional Cytotoxic Agents Related Products (32):

Cat. No. Product Name Effect Purity
  • HY-128871
    VCP-Eribulin
    VCP-Eribulin consists the ADCs linker (VCP) and Eribulin. Eribulin is a mechanistically unique microtubule inhibitor for cancer. VCP-Eribulin is an Eribulin-based agent for antibody conjugates.
  • HY-112806
    ST8155AA1
    ST8155AA1 is a part of antibody agent conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity.
  • HY-139018A
    TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride
    TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride (compound 9) is a drug-linker conjugates for ADC with potent antitumor activity by using TLR7/8 agonist 4 (HY-139018; a TLR7/8 agonist), linked via the non-cleavable ADC linker hydroxy-PEG10-acid (HY-133307).
  • HY-128893
    MC-Sq-Cit-PAB-Gefitinib
    MC-Sq-Cit-PAB-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using Gefitinib (an EGFR tyrosine kinase inhibitor), linked via the ADC linker MC-Sq-Cit-PAB.
  • HY-128905
    MC-Val-Cit-PAB-dimethylDNA31
    MC-Val-Cit-PAB-dimethylDNA31 is a agent-linker conjugate for ADC with potent antitumor activity by using dimethylDNA31, linked via the ADC linker MC-Val-Cit-PAB. DimethylDNA31 has effective bactericidal activity against persisters and stationary-phase S. aureus.
  • HY-131088
    N3-PEG8-Phe-Lys-PABC-Gefitinib
    N3-PEG8-Phe-Lys-PABC-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
  • HY-142740
    Rha-PEG3-SMCC
    Rha-PEG3-SMCC (compound 13) is a agent-linker conjugate for ADC with potent antitumor activity by using SMCC (a protein crosslinker), linked via the noncleavable ADC linker Rha-PEG3.
  • HY-144554
    Aminooxy CatB-LXR
    Aminooxy CatB-LXR (compound 10) is a agent-linker conjugates for ADC.
  • HY-139018
    TLR7/8 agonist 4 hydroxy-PEG10-acid
    TLR7/8 agonist 4 hydroxy-PEG10-acid (compound 9) is a drug-linker conjugates for ADC with potent antitumor activity by using TLR7/8 agonist 4 (HY-139018; a TLR7/8 agonist), linked via the non-cleavable ADC linker hydroxy-PEG10-acid (HY-133307).
  • HY-111555
    AmPEG6C2-Aur0131
    AmPEG6C2-Aur0131 is a agent-linker conjugate for ADC (anti-CXCR4 ADC) with potent antitumor activity by using Aur0131 (an auristatin microtubule inhibitor), linked via the non-cleavable linker AmPEG6C2.
  • HY-112805
    ST8154AA1
    ST8154AA1 is a part of antibody agent conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity.
  • HY-160756A
    Val-Cit-Exatecan TFA
    Val-Cit-Exatecan TFA is an agent-linker conjugate for ADC. Val-Cit-Exatecan TFA is composed of a DNA topoisomerase I Exatecan (HY-13631) and a cathepsin cleavable ADC linker.